Posts tagged ‘biotech marketing consulting’
June 20th, 2011
Pieter Droppert will be attending the Biotechnology Industry Association (BIO) international convention that takes place in Washington DC from June 27-30, 2011.
Pieter has shared on Biotech Strategy Blog, his top 10 sessions at BIO 2011. Topics at the meeting he plans to hear more about include personalized medicine, biomarkers, biosimilars, biologics and tissue engineering. Biotech regions from around the world will also be sharing how they promote innovation.
As he notes in his post, at BIO he will be applying the “law of two feet.” Simply put this means if the session you are in isn’t delivering the goods or ROI, it’s OK to walk out and go to another one. That is another one of the advantages of following the live-tweets at a conference, you can readily see if there’s a more interesting session going on!
Pieter will be writing about the news from BIO 2011 on Biotech Strategy Blog.
April 1st, 2011
Nanotechnology is expected to provide major breakthroughs in how drugs cross the blood-brain barrier and reach into tumors. That promise is already starting to be seen.
Research by Julia Ljubimova and her team at Cedars-Sinai Medical Center was recently published in the AACR journal, Cancer Research. They showed that biodegradable nanoparticles containing trastuzumab (herceptin), dramatically reduced HER2/neu protein activity in mice containing human HER2/neu positive breast tumors.
As Sally Church in her thoughtful post about this research on Pharma Strategy Blog, states, “it will be most interesting to see if this idea is developed clinically in human trials and whether the results will be reproducible or not.”
Nanotechnology and the development of nanoparticles that deliver drugs more effectively and with less toxicity, is an area that all new products professionals should be watching.
February 14th, 2011
As reported in the February 4, 2011 issue of Science, many genes are now covered by patents. Navigating through the intellectual property rights of others presents challenges for companies seeking to enter the market for cancer diagnostic tests.
Pieter Droppert on the Biotech Strategy Blog considers the competitive landscape at the interface of science, law and innovation. He discusses the case of Myriad Genetics whose patents for BRCA1 and BRAC2 genes, linked to breast and ovarian cancer, were recently overturned. If companies are not able to obtain patents for unaltered DNA does this present an opportunity or a set back for the biotechnology industry?
The legal decisions that flow out of the Myriad Genetics case are likely to have a major impact on the future development of personalized medicine. You can read more on Biotech Strategy Blog.